Neuren Pharmaceuticals Limited NEU

Australian inflation accelerated to 4% in August, and interest rates now sit at a 15 year high of 4.6%. That mix is putting cost pressure on households while lifting the appeal of resilient sectors. Healthcare often holds up when budgets tighten because treatment is hard to postpone. This article walks through three leading Australian healthcare stocks from a high quality screener that targets robust balance sheets and proven business models. The three stocks in focus below are a starting...

Australia’s cash rate is now at a 15 year high of 4.6%, which puts real pressure on slower growing businesses. Faster earnings growth can matter more when money is this expensive, because the market often rewards companies that can still expand profits while others struggle. This article highlights three Australian stocks from a high growth opportunity screen that analysts expect to deliver solid earnings momentum and maintain broadly healthy balance sheets. The three stocks below are only a...

Neuren Pharmaceuticals Ltd (NURPF) reports strong first-half 2026 results with USD23 million in royalties, initiates its first dividend, and advances its Koala Phase III trial.

It certainly might concern Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders to see the share price down 35% in...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...